|
EP2529621B1
(en)
|
2006-09-22 |
2016-10-05 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009262068C1
(en)
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
CN102159214A
(zh)
|
2008-07-16 |
2011-08-17 |
药品循环公司 |
用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
US7741330B1
(en)
*
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
MX380504B
(es)
|
2010-06-03 |
2025-03-12 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
JP5810157B2
(ja)
*
|
2010-07-09 |
2015-11-11 |
ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ |
プロテインキナーゼ阻害剤および処置の方法
|
|
PH12013500246A1
(en)
*
|
2010-08-10 |
2019-10-11 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
BR112013010564B1
(pt)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
Compostos heterocíclicos e composições compreendendo os mesmos
|
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
EP2694486B1
(en)
*
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EP3628665B1
(en)
|
2011-04-01 |
2022-11-02 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
|
WO2012158795A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
AU2012255860C1
(en)
|
2011-05-17 |
2015-12-10 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
DK2710007T3
(da)
*
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
|
WO2013003629A2
(en)
*
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
|
KR20140048968A
(ko)
|
2011-07-13 |
2014-04-24 |
파마시클릭스, 인코포레이티드 |
브루톤형 티로신 키나제의 억제제
|
|
DK2734205T3
(en)
|
2011-07-21 |
2018-06-14 |
Tolero Pharmaceuticals Inc |
Heterocyclic Protein Kinase Inhibitors
|
|
JP2014532658A
(ja)
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
TW201336847A
(zh)
*
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
|
US8889666B2
(en)
|
2012-02-23 |
2014-11-18 |
Taiho Pharmaceutical Co., Ltd. |
Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
|
|
JP6317320B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の塩
|
|
ES2880109T3
(es)
|
2012-03-15 |
2021-11-23 |
Celgene Car Llc |
Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
|
|
HK1206624A1
(en)
|
2012-04-11 |
2016-01-15 |
Acerta Pharma B.V. |
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
|
|
WO2013157021A1
(en)
|
2012-04-20 |
2013-10-24 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
CN104662018B
(zh)
|
2012-04-20 |
2017-10-24 |
阿迪维纳斯治疗有限公司 |
取代的杂双环化合物、组合物及其医疗应用
|
|
BR112014029718A2
(pt)
*
|
2012-05-31 |
2017-06-27 |
Pharmascience Inc |
inibidores da proteína quinase
|
|
MA37711A1
(fr)
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
|
HK1206073A1
(en)
|
2012-07-24 |
2015-12-31 |
药品循环有限责任公司 |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
KR102194611B1
(ko)
|
2012-10-04 |
2020-12-23 |
유니버시티 오브 유타 리서치 파운데이션 |
티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
|
|
JP6313772B2
(ja)
|
2012-10-04 |
2018-04-18 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
KR20150084923A
(ko)
|
2012-11-15 |
2015-07-22 |
파마시클릭스, 인코포레이티드 |
키나제 억제제로서의 피롤로피리미딘 화합물
|
|
CN103848810A
(zh)
*
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN105188371A
(zh)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk抑制剂及其用途
|
|
KR20150119401A
(ko)
|
2013-02-22 |
2015-10-23 |
다이호야쿠힌고교 가부시키가이샤 |
3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
|
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
|
WO2014152114A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as btk inhibitors
|
|
EP2970291B1
(en)
*
|
2013-03-15 |
2022-05-11 |
Janssen Pharmaceutica, N.V. |
Processes and intermediates for preparing a medicament
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
PL2989106T3
(pl)
|
2013-04-25 |
2017-08-31 |
Beigene, Ltd. |
Połączone związki heterocykliczne jako inhibitory kinazy białkowej
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
AU2014293013A1
(en)
|
2013-07-26 |
2016-03-17 |
Race Oncology Ltd. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
|
CA2920534A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics Llc |
Methods for the treatment of her2 amplified cancer
|
|
TWI603971B
(zh)
*
|
2013-08-22 |
2017-11-01 |
Taiho Pharmaceutical Co Ltd |
Novel quinoline substituted compounds
|
|
ES3069593T3
(en)
|
2013-08-23 |
2026-06-09 |
Neupharma Inc |
Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CN105764896A
(zh)
|
2013-09-30 |
2016-07-13 |
药品循环有限责任公司 |
布鲁顿氏酪氨酸激酶的抑制剂
|
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
US9624201B2
(en)
|
2013-12-13 |
2017-04-18 |
Hoffmann-La Roche Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
SG11201605417QA
(en)
*
|
2014-02-03 |
2016-08-30 |
Cadila Healthcare Ltd |
Heterocyclic compounds
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
EP3134418A4
(en)
|
2014-04-23 |
2018-01-03 |
The Research Foundation for The State University of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
|
CN105017256A
(zh)
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
|
WO2015172713A1
(zh)
*
|
2014-05-13 |
2015-11-19 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
|
CN104086551B
(zh)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
化合物及其制备方法和用途
|
|
GB201410430D0
(en)
*
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
CA2959602A1
(en)
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
US9545407B2
(en)
|
2014-08-07 |
2017-01-17 |
Pharmacyclics Llc |
Formulations of a bruton's tyrosine kinase inhibitor
|
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
|
WO2016050422A1
(en)
*
|
2014-10-01 |
2016-04-07 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
EP3042903B1
(en)
|
2015-01-06 |
2019-08-14 |
Impetis Biosciences Ltd. |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
|
MA41350A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
US10266535B2
(en)
|
2015-01-21 |
2019-04-23 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Inhibitor of FLT3 kinase and use thereof
|
|
CN105859721B
(zh)
*
|
2015-01-22 |
2018-04-17 |
浙江京新药业股份有限公司 |
一种伊布鲁替尼的制备方法
|
|
RU2712440C2
(ru)
*
|
2015-02-12 |
2020-01-29 |
Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд |
Способ получения ибрутиниба
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of proton tyrosine kinase inhibitor
|
|
US10045990B2
(en)
|
2015-03-04 |
2018-08-14 |
Arizona Board Of Regents On Behalf Of Arizona State University |
ERBB4 inhibitors and methods of use thereof
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
CN106146516B
(zh)
*
|
2015-04-20 |
2019-02-15 |
北京睿创康泰医药研究院有限公司 |
依鲁替尼药物杂质的制备方法
|
|
EP3912979B1
(en)
*
|
2015-06-03 |
2026-03-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9394312B1
(en)
*
|
2015-06-14 |
2016-07-19 |
Mark Quang Nguyen |
Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
|
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US10611766B2
(en)
|
2015-09-16 |
2020-04-07 |
Loxo Oncology Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
|
CN114605327B
(zh)
|
2015-12-16 |
2025-03-11 |
洛克索肿瘤学股份有限公司 |
可用作激酶抑制剂的化合物
|
|
WO2017111179A1
(en)
|
2015-12-24 |
2017-06-29 |
Takeda Pharmaceutical Company Limited |
Cocrystal, production method thereof, and medicament containing cocrystal
|
|
ES2875384T3
(es)
*
|
2016-01-05 |
2021-11-10 |
Jiangsu Hengrui Medicine Co |
Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo
|
|
FI3405177T3
(fi)
*
|
2016-01-19 |
2026-06-03 |
Janssen Pharmaceutica Nv |
Btk:n estäjää käsittäviä formulaatioita/koostumuksia
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
AU2017208998B2
(en)
*
|
2016-01-21 |
2021-07-15 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Bruton's tyrosine kinase inhibitors
|
|
CN106995446B
(zh)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
布鲁顿酪氨酸激酶抑制剂制备方法
|
|
EP3426637B1
(en)
|
2016-03-11 |
2022-02-09 |
Angel Pharmaceutical Co., Ltd. |
Compounds and methods for modulating bruton's tyrosine kinase
|
|
CN107383013B
(zh)
*
|
2016-05-16 |
2020-03-31 |
苏州信诺维医药科技有限公司 |
作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
|
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
CN109843858B
(zh)
*
|
2016-08-15 |
2023-05-05 |
润新生物公司 |
某些化学实体、组合物及方法
|
|
IL293319B1
(en)
|
2016-08-16 |
2026-01-01 |
Beone Medicines Ltd |
Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
AU2017350440B2
(en)
|
2016-10-31 |
2023-01-12 |
Taiho Pharmaceutical Co., Ltd. |
Selective inhibitor of exon 20 insertion mutant EGFR
|
|
JOP20190113A1
(ar)
*
|
2016-11-18 |
2019-05-15 |
Biocad Joint Stock Co |
مثبطات بروتون تيروزين كيناز
|
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
WO2018145280A1
(zh)
*
|
2017-02-09 |
2018-08-16 |
合肥合源药业有限公司 |
Flt3激酶抑制剂或其盐的晶型及其制备方法
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
FI3677266T3
(fi)
|
2017-09-01 |
2024-03-22 |
Taiho Pharmaceutical Co Ltd |
Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
|
|
TW201922256A
(zh)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
治療淋巴樣惡性疾病之方法
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
CN108191871B
(zh)
*
|
2018-01-02 |
2020-02-18 |
成都倍特药业有限公司 |
新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
MX2020010556A
(es)
|
2018-04-13 |
2021-03-02 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
CN109134472B
(zh)
*
|
2018-09-20 |
2020-02-11 |
浙江理工大学 |
一种3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺的合成工艺
|
|
CN110964016B
(zh)
*
|
2018-09-29 |
2021-05-28 |
南京药捷安康生物科技有限公司 |
氨基降茨烷衍生物及其制备方法与应用
|
|
CN109369654A
(zh)
*
|
2018-11-20 |
2019-02-22 |
山东大学 |
1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
|
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药（上海）有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
|
HUE072069T2
(hu)
|
2019-02-12 |
2025-10-28 |
Sumitomo Pharma America Inc |
2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
|
|
CN118027041A
(zh)
|
2019-05-31 |
2024-05-14 |
西藏海思科制药有限公司 |
一种btk抑制剂环衍生物及其制备方法和药学上的应用
|
|
EP3981399A4
(en)
|
2019-06-10 |
2023-05-31 |
BeiGene Switzerland GmbH |
ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
|
|
CN110606848A
(zh)
*
|
2019-08-27 |
2019-12-24 |
药雅科技(上海)有限公司 |
一种5-氮杂吲哚衍生物Bruton′s酪氨酸激酶抑制剂及其制备方法与用途
|
|
AU2020365951B2
(en)
|
2019-10-14 |
2026-07-16 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
WO2021089395A1
(en)
|
2019-11-08 |
2021-05-14 |
Nerviano Medical Sciences S.R.L. |
Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
|
|
KR102993352B1
(ko)
|
2019-12-20 |
2026-07-22 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
|
|
CA3168146A1
(en)
|
2020-01-20 |
2021-07-29 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
|
|
WO2021150723A1
(en)
|
2020-01-22 |
2021-07-29 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
CN113943294A
(zh)
*
|
2020-07-15 |
2022-01-18 |
成都海博为药业有限公司 |
一种作为btk抑制剂的化合物及其制备方法与用途
|
|
US20240002387A1
(en)
*
|
2020-11-25 |
2024-01-04 |
Haisco Pharmaceuticals Pte. Ltd. |
Method for preparing btk degrading agent
|
|
CA3201936A1
(en)
|
2020-12-10 |
2022-06-16 |
Minhua Chen |
Crystal form of tolebrutinib and preparation method thereof
|
|
IL303834A
(en)
|
2020-12-23 |
2023-08-01 |
Genzyme Corp |
4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
|
|
CN113004246B
(zh)
*
|
2021-02-22 |
2022-02-01 |
广西医科大学 |
1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
AU2023372386A1
(en)
|
2022-10-31 |
2025-05-08 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|